Tailor-made drug treatment for children: creation of an infrastructure for data-sharing and population PK-PD modeling.
暂无分享,去创建一个
Meindert Danhof | Dick Tibboel | Catherijne A J Knibbe | Ibrahim Ince | D. Tibboel | M. Danhof | C. Knibbe | S. D. de Wildt | Saskia N de Wildt | Ibrahim Ince
[1] V. Hasselblad,et al. Pediatric Antihypertensive Trial Failures: Analysis of End Points and Dose Range , 2008, Hypertension.
[2] T. Johnson. Modelling approaches to dose estimation in children. , 2005, British journal of clinical pharmacology.
[3] S. Marsh,et al. Developmental Changes in Human Liver CYP2D6 Expression , 2008, Drug Metabolism and Disposition.
[4] France Mentré,et al. Metrics for External Model Evaluation with an Application to the Population Pharmacokinetics of Gliclazide , 2006, Pharmaceutical Research.
[5] Susan M Abdel-Rahman,et al. Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.
[6] Meindert Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. , 2007, Annual review of pharmacology and toxicology.
[7] G. Kearns,et al. Pharmacokinetics of Gatifloxacin in Infants and Children , 2005, Antimicrobial Agents and Chemotherapy.
[8] D. Tibboel,et al. Pharmacokinetics and Pharmacodynamics of Midazolam and Metabolites in Nonventilated Infants after Craniofacial Surgery , 2006, Anesthesiology.
[9] W. Hop,et al. Use of Saliva in Therapeutic Drug Monitoring of Caffeine in Preterm Infants , 2001, Therapeutic drug monitoring.
[10] G. Levy,et al. Impact of pharmacodynamic variability on drug delivery(1). , 1998, Advanced drug delivery reviews.
[11] E N Jonsson,et al. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. , 1999, Computer methods and programs in biomedicine.
[12] A. van Hecken,et al. Comparative pharmacokinetics of ceftazidime and moxalactam , 1982, Antimicrobial Agents and Chemotherapy.
[13] Shinya Ito,et al. Challenges for drug studies in children: CYP3A phenotyping as example. , 2009, Drug discovery today.
[14] D. Tibboel,et al. Propofol Pharmacokinetics and Pharmacodynamics for Depth of Sedation in Nonventilated Infants after Major Craniofacial Surgery , 2006, Anesthesiology.
[15] Mats O. Karlsson,et al. Three new residual error models for population PK/PD analyses , 1995, Journal of Pharmacokinetics and Biopharmaceutics.
[16] D. Phelps. E-ferol: what happened and what now? , 1984, Pediatrics.
[17] Maurizio Bonati,et al. Survey of unlicensed and off label drug use in paediatric wards in European countries , 2000, BMJ : British Medical Journal.
[18] M Danhof,et al. Relevance of the Application of Pharmacokinetic-Pharmacodynamic Modelling Concepts in Drug Development , 1997, Clinical pharmacokinetics.
[19] D. Tibboel,et al. Covariates of tramadol disposition in the first months of life. , 2008, British journal of anaesthesia.
[20] Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. , 1959, A.M.A. journal of diseases of children.
[21] W. Hop,et al. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. , 1995, British journal of clinical pharmacology.
[22] Lewis B. Sheiner,et al. Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects , 1992, Journal of Pharmacokinetics and Biopharmaceutics.
[23] W. Silverman,et al. A difference in mortality rate and incidence of kernicterus among premature infants allotted to two prophylactic antibacterial regimens. , 1956, Pediatrics.
[24] K. Covinsky,et al. Assessing the Generalizability of Prognostic Information , 1999, Annals of Internal Medicine.
[25] S. Parker,et al. The use of the dried blood spot sample in epidemiological studies. , 1999, Journal of clinical pathology.
[26] D. Tibboel,et al. Unapproved and off-label use of drugs in a children's hospital. , 2000, The New England journal of medicine.
[27] J. Burns. Research in children , 2003, Critical care medicine.
[28] Michel Tod,et al. Facilitation of Drug Evaluation in Children by Population Methods and Modelling , 2008, Clinical pharmacokinetics.
[29] T. J. Preston,et al. Induction of CYP1A2 activity by carbamazepine in children using the caffeine breath test. , 1998, British journal of clinical pharmacology.
[30] Sihe Wang,et al. Recent development in application of high performance liquid chromatography-tandem mass spectrometry in therapeutic drug monitoring of immunosuppressants. , 2008, Journal of immunological methods.
[31] Phyllis N Butow,et al. Clinical trials in children , 2004, The Lancet.
[32] G H Guyatt,et al. Users' guides to the medical literature: XXII: how to use articles about clinical decision rules. Evidence-Based Medicine Working Group. , 2000, JAMA.
[33] B. Stricker,et al. Unlicensed and off-label drug use in a paediatric ward of a general hospital in the Netherlands , 2002, European Journal of Clinical Pharmacology.
[34] D. Tibboel,et al. Pharmacogenetics and paediatric drug development: issues and consequences to labelling and dosing recommendations , 2007, Expert opinion on pharmacotherapy.
[35] P. McNamara,et al. Using ontogeny information to build predictive models for drug elimination. , 2008, Drug discovery today.
[36] G. Kearns,et al. Population Pharmacokinetic Model for Gatifloxacin in Pediatric Patients , 2007, Antimicrobial Agents and Chemotherapy.
[37] J. Leeder. Ontogeny of drug-metabolizing enzymes and its influence on the pathogenesis of adverse drug reactions in children , 2001 .